Clinical Trial Feasibility – Acute Myeloid Leukemia (AML)

Clinical Trial Summary

Phase 1 & II, Interventional, multi-center, randomized, single-arm, multiple ascending dose study to evaluate the safety, pharmacokinetics & pharmacodynamics in patients diagnosed with AML

The purpose of this study is to determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CXD in patients with relapsed/refractory acute myeloid leukemia (AML).

Key Inclusion Criteria:

  • Age ≥ 18 years at the time of screening.
  • Subjects must have a documented diagnosis of acute myeloid leukemia (AML) (WHO 2016)
  • Subjects non-eligible for intensive chemotherapy as first-line, second-line, or third-line treatment.
  • Written informed consent and any locally required authorization
  • Liver Function Tests: AST and ALT ≤ 3 × ULN, and serum TBL ≤ 1.5 × ULN, unless consistent with Gilbert’s syndrome for which TBL ≤ 2.5 × ULN is allowed.
  • CrCL ≥ 40 mL/min 6. Female patients of childbearing potential who are sexually active with a non sterilized male partner must use at least one highly effective method of contraception from 7 days post-screening and must agree to continue using such precautions for 90 days after the last dose of investigational product.
  • Non Sterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from 7 days post-screening and for 90 days after receipt of the last dose of investigational product

Key Exclusion Criteria:

  • Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections at the time of screening.
  • Patients at risk of non-disease related major bleeding (eg, recent GI hemorrhage or neurosurgery, within the previous 21 days).
  • Current severe active systemic disease including active concurrent malignancy
  • Received cytotoxic chemotherapy within 21 days (or 42 days for nitrosoureas or mitomycin C) prior to the first scheduled dose of CXD.
  • Received an investigational drug within 14 days of the first scheduled dose of CXD or not recovered from associated toxicities.
  • Received any major surgery (as defined by the Investigator), radiotherapy, or immunotherapy (including immune checkpoint inhibitors and adoptive cellular therapy such as autologous or donor NK cell or T lymphocyte infusions (e.g. CAR -T cells)) within 28 days of the first scheduled dose of CXD.
  • Patients who have previously received an autologous SCT, are excluded if less than 120 days have elapsed from the time of transplant or the patient has not recovered from transplant-associated toxicities prior to the first scheduled dose of CXD.
  • History of liver cirrhosis, liver fibrosis or prior liver irradiation regardless of the time interval (not including total body irradiation administered during allogeneic SCT).
  • Failure to recover from all prior treatment-related non-hematological toxicities to ≤ Grade 1 prior to the first scheduled dose of CXD (except for alopecia and neuropathy).
  • Central nervous system (CNS) disease that is untreated, symptomatic, or requires therapy to control symptoms.

Would you recommend investigators for this trial? Click here

Do you have any comments / questions? Click here


Complete the following details to participate in this clinical trial feasibility.

Feasibility Form

By submitting this response, you will be expressing your interest in the new opportunities for clinical trials and / or consulting with Credevo.
Please note that all questions are required to be answered.


General Introduction


Experience

Medical experience

Clinical trial experience
Number of clinical trials conducted till now?

Previous Trials


Trial 1


Trial 2


Trial 3


Site Details

Site name
Type of site

Site Address
 

Country
Site contact number

Therapeutic areas your site deals with


Site facilities

Clinical Trial Staff (Number)
Professional clinical staff
Study coordinators

Doctors
Nurses

Treatment facilities at your site
Do you have access to MRI scan?
Do you have access to PET scan?
Does your site have special monitoring chamber for clinical trials?
Do your site have clinical/pathology laboratory?
Medical records room (for documents & files)
Secured drug storage (locking and secure facility)
Is Investigator GCP trained?
Does the site have GCP trained staff?

How do you/site recruit patients?

Patients inflowAdvertisementsPostersReferred by someoneTelevisionWebsiteOthers


Project Feasibility Questionnaire

Based on the Clinical Trial Summary above, provide your answers to participate in this clinical trial

Q. How many patients visit your site with AML monthly?
Q. How many patients do you expect to recruit based on the inclusion and exclusion criteria?
Q. Is your site presently enrolling or anticipating participation in any other studies that would compete for the same patient population within our study timelines?
Q. What is the standard line of treatment you use to treat the patients for this indication?
Q. Which is the preferable language for Informed Consent Form ?
Q. For scheduling a site visit (for selection/ initiation /monitoring /closeout), how many days before actual site visit, would you need our monitor to inform and take appointment with you?
Q. What is the time period for agreement/contract with your site for this project?
Q. Provide the requirements of IRB for review & approval?
Q. How many days/months prior to the scheduled meeting must the IEC/IRB submission take place?
Q. How long does it typically take from submission to receipt of approval letter from IRB/EC?
Q. Does your site pursue IRB/EC approval at the same time as contract & budget completion?
Q. Please share your feedback or suggestion, if any.


By clicking "Submit" button, you accept our updated terms & conditions and privacy policy.


Would you recommend investigators for this trial? Click here

Do you have any comments/questions? Click here


Leave a Reply

Your email address will not be published. Required fields are marked *

.